Murphy & Mullick Capital Management Corp Makes New Investment in ICU Medical, Inc. (NASDAQ:ICUI)

Murphy & Mullick Capital Management Corp acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 337 shares of the medical instruments supplier’s stock, valued at approximately $52,000.

Other hedge funds also recently modified their holdings of the company. Intech Investment Management LLC bought a new position in ICU Medical in the 3rd quarter valued at about $815,000. Charles Schwab Investment Management Inc. increased its stake in shares of ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock worth $54,868,000 after purchasing an additional 27,927 shares during the period. Citigroup Inc. lifted its holdings in ICU Medical by 100.4% during the 3rd quarter. Citigroup Inc. now owns 28,965 shares of the medical instruments supplier’s stock worth $5,278,000 after purchasing an additional 14,512 shares during the last quarter. Cerity Partners LLC boosted its stake in ICU Medical by 33.2% in the 3rd quarter. Cerity Partners LLC now owns 9,846 shares of the medical instruments supplier’s stock valued at $1,794,000 after purchasing an additional 2,454 shares during the period. Finally, FMR LLC grew its holdings in ICU Medical by 2,676.6% in the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after buying an additional 100,345 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. StockNews.com cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. Finally, Raymond James set a $97.00 target price on shares of ICU Medical in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and an average price target of $168.67.

ICU Medical Stock Down 3.0 %

Shares of NASDAQ ICUI opened at $144.28 on Friday. ICU Medical, Inc. has a 52 week low of $93.36 and a 52 week high of $196.26. The stock’s fifty day moving average is $154.89 and its 200 day moving average is $164.01. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a market capitalization of $3.54 billion, a P/E ratio of -31.57 and a beta of 0.73.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.